HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis

HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis

Abstract Background Our study aimed to compare the predictive performance of different hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B patients receiving entecavir or tenofovir, including discrimination, calibration, negative predictive value (NPV) in low-risk, and proportion...

Full description

Bibliographic Details
Main Authors:	Xiaolan Xu, Lushun Jiang, Yifan Zeng, Liya Pan, Zhuoqi Lou, Bing Ruan
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	Virology Journal
Subjects:	Risk factors Discrimination Calibration Predictive value of tests Surveillance
Online Access:	https://doi.org/10.1186/s12985-023-02145-5

Similar Items

Serum cytokine profiles and chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Chunmin Lou
Published: (2024-02-01)

Cost-effectiveness of tenofovir alafenamide and entecavir in chronic hepatitis B in Saudi Arabia
by: Ahmed Al-Jedai
Published: (2024-01-01)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
by: Chih-Wen Huang, et al.
Published: (2023-03-01)

Evaluation of the Efficacy of Entecavir and Tenofovir in the Treatment of Chronic Hepatitis B: A Retrospective Study
by: Arzu ŞENOL, et al.
Published: (2019-12-01)

Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024-02-01)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
by: Zili Hu, et al.
Published: (2022-03-01)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
by: Shun Ishido, et al.
Published: (2023-08-01)

Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy
by: Zheng Z, et al.
Published: (2023-11-01)

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
by: Xingmei Liao, et al.
Published: (2023-11-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
by: Fa- Da Wang, et al.
Published: (2023-09-01)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
by: Zekun Liu, et al.
Published: (2023-11-01)

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
by: Hsin-Wei Fang, et al.
Published: (2024-04-01)

Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy”
by: Meng-Ju Lin, et al.
Published: (2024-02-01)

Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model
by: Chun-Huang Lai, et al.
Published: (2024-02-01)

Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients
by: Yi-Jie Huang, et al.
Published: (2023-12-01)

Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma
by: Weili Qi, et al.
Published: (2023-10-01)

Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis
by: Xiaoxian Yang, et al.
Published: (2022-11-01)

Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study
by: Yu-Han Huang, et al.
Published: (2023-12-01)

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study
by: Wenting Peng, et al.
Published: (2023-05-01)

Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis
by: Tan, Darren Jun Hao, et al.
Published: (2023)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
by: Tzu-Ning Tseng, et al.
Published: (2022-05-01)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01)

Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China
by: Xiaolan Xu, et al.
Published: (2023-02-01)

Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis
by: Neng Wang, et al.
Published: (2023-11-01)

Predicting Type Two Diabetes and Determination of Effectiveness of Risk Factors Applying Logistic Regression Model
by: M Aram-Ahmaddi, et al.
Published: (2014-03-01)

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
by: Jihye Kim, et al.
Published: (2023-05-01)

Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir
by: Diana Horta, et al.

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide
by: I. Vern Lim, et al.
Published: (2023-08-01)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
by: Jianming Yang, et al.
Published: (2023-01-01)

Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail
by: Hyunwoo Oh, et al.
Published: (2022-05-01)

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial
by: Li-Xin Pan, et al.
Published: (2024-01-01)

Experience of entecavir therapy in chronic hepatitis B
by: E. V. Esaulenko, et al.
Published: (2014-09-01)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
by: Kanako Yoshida, et al.
Published: (2021-02-01)

Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
by: Xiaolan Xu, et al.
Published: (2022-10-01)

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by: Soon Kyu Lee, et al.
Published: (2024-02-01)

Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models
by: Sherly X. Li, et al.
Published: (2021-10-01)

Evaluation of the Performance of PRISM III and PIM II Scores in a Tertiary Pediatric Intensive Care Unit
by: Büşra Uzunay Gündoğan, et al.
Published: (2023-04-01)

Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia
by: Faisal M Sanai, et al.
Published: (2024-01-01)